Michele Cavo, MD, PhD, Bologna University School of Medicine, Bologna, Italy, highlights the importance of CD38-targeting triplets for the treatment of multiple myeloma, drawing focus on the promise that these combination therapies provide for patients with relapsed/refractory (R/R) disease. Prof. Cavo also mentions the improved progression-free survival (PFS) observed in several triplet combinations such as a monoclonal antibody plus pomalidomide and dexamethasone. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.